138 related articles for article (PubMed ID: 22913768)
21. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
22. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
[TBL] [Abstract][Full Text] [Related]
23. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis.
Chao C; Rodriguez R; Page JH; Yang SJ; Huynh J; Chia VM
Leuk Lymphoma; 2015 Jan; 56(1):72-9. PubMed ID: 24684228
[TBL] [Abstract][Full Text] [Related]
24. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim.
Ng JH; Ang XY; Tan SH; Tao M; Lim ST; Chan A
Acta Haematol; 2011; 125(3):107-14. PubMed ID: 21109731
[TBL] [Abstract][Full Text] [Related]
25. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
Lyman GH; Morrison VA; Dale DC; Crawford J; Delgado DJ; Fridman M; ;
Leuk Lymphoma; 2003 Dec; 44(12):2069-76. PubMed ID: 14959849
[TBL] [Abstract][Full Text] [Related]
26. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
[TBL] [Abstract][Full Text] [Related]
27. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
[TBL] [Abstract][Full Text] [Related]
28. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
29. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
30. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
[TBL] [Abstract][Full Text] [Related]
31. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Pettengell R; Johnsen HE; Lugtenburg PJ; Silvestre AS; Dührsen U; Rossi FG; Schwenkglenks M; Bendall K; Szabo Z; Jaeger U
Support Care Cancer; 2012 Mar; 20(3):647-52. PubMed ID: 22101611
[TBL] [Abstract][Full Text] [Related]
32. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
[TBL] [Abstract][Full Text] [Related]
34. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.
Blay JY; Chauvin F; Le Cesne A; Anglaret B; Bouhour D; Lasset C; Freyer G; Philip T; Biron P
J Clin Oncol; 1996 Feb; 14(2):636-43. PubMed ID: 8636781
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis.
Kim YR; Kim SJ; Park Y; Oh SY; Yun HJ; Mun YC; Kim JS;
Korean J Intern Med; 2021 Sep; 36(5):1181-1189. PubMed ID: 34265889
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
[TBL] [Abstract][Full Text] [Related]
37. Risk of mortality in patients with cancer who experience febrile neutropenia.
Lyman GH; Michels SL; Reynolds MW; Barron R; Tomic KS; Yu J
Cancer; 2010 Dec; 116(23):5555-63. PubMed ID: 20715160
[TBL] [Abstract][Full Text] [Related]
38. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
39. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Weycker D; Li X; Figueredo J; Barron R; Tzivelekis S; Hagiwara M
Support Care Cancer; 2016 May; 24(5):2309-2316. PubMed ID: 26607482
[TBL] [Abstract][Full Text] [Related]
40. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]